XDx Gets CTAF Recommendation for AlloMap Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – XDx today said that the California Technology Assessment Forum has recommended the use of its AlloMap gene expression test.

The Brisbane, Calif.-based firm said that CTAF, which is a non-profit entity sponsored by Blue Shield of California to assess new and emerging medical technology, agreed that AlloMap met all five technology assessment criteria for safety, effectiveness, and improvement in health outcomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.